Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CS-7017 Plus Erlotinib in Advanced NSCLC After Failure of First-Line Therapy
2009-016083-36Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing CS-7017 + erlotinib with Erlotinib alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2010; status: completed.
02
Drugs
efatutazoneerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-016083-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016083-36.